Authors

• Ivica Bošnjak — University Hospital Centre Osijek, Osijek, Croatia — ORCID: 0000-0002-0223-4287
• Dražen Bedeković — University Hospital Centre Osijek, Osijek, Croatia — ORCID: 0000-0002-8076-4398
• Kristina Selthofer-Relatić — University Hospital Centre Osijek, Osijek, Croatia — ORCID: 0000-0002-9890-6489
• Hrvoje Roguljić — University Hospital Centre Osijek, Osijek, Croatia — ORCID: 0000-0002-3747-9305
• Ines Bilić-Ćurčić — University Hospital Centre Osijek, Osijek, Croatia — ORCID: 0000-0002-8861-5987

Keywords

galectin-3, coronary artery disease, biomarker, chronic coronary syndrome

DOI

Full Text

**Background**: The aim of this study is to examine possible association between serum galectin-3 values and the presence of significant atherosclerotic epicardial artery disease in patients with chronic coronary syndrome. **Patients and Methods**: Subjects with suspected coronary artery disease and indication for coronary angiography were included in study. Subject were divided in three groups: a) subject with indication for PCI, b) subject with indication for CABG and control group (without coronary artery disease). Galectin-3 value was measured by enzyme immunoassay (EIA) test. **Results**: T-test and ANOVA variance analysis was performed for statistically analysis (SPSS program, version 17.0). The mean value of galectin-3 in the study group was statistically higher than in control group (19.98 ng/ml vs. 9.51 ng/ml, p<0.001). In subgroup analysis there was no statistically significant difference in the values ​​of galectin-3 between the PCI and CABG groups (18.84 ng/ml vs. 21.27 ng/ml (t=7.417, p<0.001). **Conclusion**: Galectin-3 has shown potential to be reliable marker for assessment of significant coronary disease existence as well as a predictor of adverse cardiovascular events (1-3).

Literature

1. Li M, Guo K, Huang X, Feng L, Yuan Y, Li J, et al. Association Between Serum Galectin-3 Levels and Coronary Stenosis Severity in Patients With Coronary Artery Disease. Front Cardiovasc Med. 2022 February 7;9:818162. https://doi.org/10.3389/fcvm.2022.818162
2. Blanda V, Bracale UM, Di Taranto MD, Fortunato G. Galectin-3 in Cardiovascular Diseases. Int J Mol Sci. 2020 December 3;21(23):9232. https://doi.org/10.3390/ijms21239232
3. Bosnjak I, Bedekovic D, Selthofer-Relatic K, Billic-Curcic I. Galectin-3: A Heart Failure Biomarker as Sign of Active Coronary Heart Disease. World J Cardiovasc Dis. 2017;7(11):373–9. https://doi.org/10.4236/wjcd.2017.711035